MARKET

TENX

TENX

Tenax Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.120
+0.020
+0.95%
After Hours: 2.120 0 0.00% 17:48 03/08 EST
OPEN
2.280
PREV CLOSE
2.100
HIGH
2.290
LOW
2.062
VOLUME
248.10K
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.2500
MARKET CAP
30.77M
P/E (TTM)
-1.7624
1D
5D
1M
3M
1Y
5Y
Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overv...
BusinessWire · 4d ago
BRIEF-Tenax Therapeutics, Inc. Expands Board Of Directors
reuters.com · 6d ago
Tenax Therapeutics, Inc. Expands Board of Directors
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced the appointment of four new members to its b...
BusinessWire · 6d ago
IBM, GSAT among premarket losers
Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenue b...
Seekingalpha · 01/22 13:29
TENX: Tenax Picks Up PH Precision Med
By John Vandermosten, CFA NASDAQ:TENX Tenax Acquires PH Precision Med Tenax Therapeutics, Inc. (NASDAQ:TENX) announced yesterday the acquisition of privately held, clinical stage PH Precision Med (PHPM) in an equity deal valued at approximately $21.6 milli...
Zacks Small Cap Research · 01/20 15:30
TENX: Tenax Picks Up PH Precision Med
By John Vandermosten, CFA NASDAQ:TENX Tenax Acquires PH Precision Med Tenax Therapeutics, Inc. (NASDAQ:TENX) announced yesterday the acquisition of privately held, clinical stage PH Precision Med (PHPM) in an equity deal valued at approximately $21.6 milli...
Zacks Small Cap Research · 01/20 15:30
TENX: Tenax Picks Up PH Precision Med
Zacks Small Cap Research · 01/20 15:30
Tenax Therapeutics Schedules Conference Call To Discuss Its Transformative Acquisition Of PH Precision Med For Jan. 21, 2021
Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med -Conference to be held at 4:30 pm EST on January 21, 2021- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty
Benzinga · 01/20 12:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TENX. Analyze the recent business situations of Tenax Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TENX stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 3.43M
% Owned: 23.62%
Shares Outstanding: 14.51M
TypeInstitutionsShares
Increased
4
35.54K
New
6
-441.22K
Decreased
4
268.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Director
Ronald Blanck
President/Chief Financial Officer
Michael Jebsen
Chief Executive Officer/Director
Anthony DiTonno
Executive Vice President
Douglas Hay
Executive Vice President
Doug Randall
Other/Director
Stuart Rich
Other
Paula Bokesch
Director
I. Keith Maher
Director
June Almenoff
Director
Steven Boyd
Director
Michael Davidson
Director
Delcan Doogan
Director
Keith Maher
Director
James Mitchum
Director
Gerald Proehl
Independent Director
Gregory Pepin
Independent Director
Chris Rallis
No Data
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Webull offers kinds of Tenax Therapeutics Inc stock information, including NASDAQ:TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.